Clinical Trial News and Research

RSS

Panzem (2-methoxyestradiol ) drug a possible candidate for breast cancer treatment

A Mayo Clinic study of a drug that has shown promise in treating sarcoma, lung and brain cancers, demonstrates that the drug may also be effective in treating breast cancer, in particular the spread of breast cancer.

2 Nov 2007

Whole parasite malaria vaccine to be manufactured for clinical trials

Sanaria Inc. and the PATH Malaria Vaccine Initiative has officially opened a one-of-a-kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.

29 Oct 2007

Surgery, radiation gives early survival advantage in bile duct cancer

Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.

28 Oct 2007

Mindfulness-based stress reduction study

A researcher at the University at Buffalo's Research Institute on Addictions (RIA) is initiating a study of "mindfulness-based stress reduction," a technique often used in behavioral medicine for stress reduction but not before as an adjunct in the treatment of alcohol use disorders.

28 Oct 2007

Education program leads to lasting improvement of cancer knowledge in African Americans

Disparities in access to health care and education hinder minorities and socioeconomically disadvantaged populations from receiving needed cancer services and often lead to delayed cancer diagnoses.

28 Oct 2007

Positive results for novel anti-cancer drug ECO-4601

Researchers report positive results from a Phase I/II clinical trial of a novel anti-cancer drug which offers two modes of action.

24 Oct 2007

Oncolytics Biotech receives approval for UK clinical trial of of REOLYSIN

Oncolytics Biotech Inc. has announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers.

24 Oct 2007

Genetics of alcoholism

While both environmental and genetic factors contribute to the risk of developing alcohol dependence, it is believed to be a largely heritable – 52 to 64 percent – disease.

24 Oct 2007

Potent inhibitor of Kinesin CENP-E demonstrates tumor cell inhibition

A first-in-class, targeted investigational therapy specifically designed to inhibit a single protein that functions only during cell division shows potent activity in a broad range of cancer cell lines, say researchers from GlaxoSmithKline.

24 Oct 2007

Combo therapy flavopiridol and cisplatin shows promise for recurrent ovarian cancer resistant to platinum therapy

Mayo Clinic has reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy.

24 Oct 2007

SPIRIT III trial shows fewer major adverse cardiac events

Late breaking results from the SPIRIT III trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that after 12 months, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent.

24 Oct 2007

Experimental cancer pharmaceuticals under trial

A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro: Abstract A 111.

24 Oct 2007

Zinc can help nursing home residents who are susceptible to pneumonia

When elderly nursing home residents contract pneumonia, it is a blow to their already fragile health.

22 Oct 2007

Stem cells from a person's own umbilical cord effectively treat blood and immune disorders, juvenile diabetes

Two separate data abstracts displayed at the annual scientific meeting of the AABB - an international association of medical professionals and institutions focused on transfusion, transplantation and cellular therapy - highlight the increasing therapeutic use of autologous (one's own) cord blood stem cells for transplant and regenerative medicine, including treatments for blood and immune disorders, juvenile diabetes and neurological repair.

22 Oct 2007

FDA approves approved Ixempra (ixabepilone) for advanced breast cancer

The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.

22 Oct 2007

Endobronchial valve improves quality of life in emphysema patients

Emphysema patients whose lungs are implanted with a pencil eraser-sized, one-way endobronchial valve experience significantly improved measures of lung function and report better quality of life, University of Pittsburgh School of Medicine researcher Frank C. Sciurba, M.D., reported today at CHEST 2007, the annual meeting of the American College of Chest Physicians.

22 Oct 2007

Human cytomegalovirus may help doctors treat glioblastoma multiforme

A common human virus may prove useful in attacking the deadliest form of brain tumors, according to a study by researchers at Duke's Preston Robert Tisch Brain Tumor Center.

22 Oct 2007

Smurfs a major cause of osteoarthritis

A new clinical trial seeks to predict who is most likely to experience osteoarthritis, and to test whether an experimental treatment can prevent it altogether.

19 Oct 2007

New biomaterial from Rutgers

A revolutionary, new biomaterial, developed at the New Jersey Center for Biomaterials (NJCBM) at Rutgers University, has moved from the lab bench to field testing in record time.

19 Oct 2007

Random drug and alcohol testing does not reliably keep student-athletes from using

In fact, the mere presence of drug testing increases some risk factors for future substance use, Oregon Health & Science University researchers report. Their findings are published in the November issue of the Journal of Adolescent Health, the journal of the Society for Adolescent Medicine.

19 Oct 2007